Five Prime Enters Transition Phase; Multiple Trials Planned In Next 12 Months

 
• By Lucie Ellis-Taitt

Five Prime, in partnership with immunotherapy giant Bristol-Myers Squibb, will launch several pivotal trials in the next 12 months for its lead compound cabiralizumab – both in combination with Opdivo in cancer and as a monotherapy in orphan disease PVNS.

Butterfly
R&D progress has pushed Five Prime into a 'transition phase,' says CEO • Source: Shutterstock

More from Strategy

More from Business